New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors

Haemophilia

Volumn 14, Issue SUPPL. 4, 2008, Pages 20-27

  Dargaud, Yesim ^a   Lambert, T ^b   Trossaert, M ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Centre for the Treatment of Haemophilic Patients   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Haemophilia; Inhibitors; Recombinant factor VIIa; Therapy; Thrombin generation; Thromboclastography

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ALGORITHM; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING TEST; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; ILIOPSOAS HEMATOMA; INDIVIDUALIZATION; LABORATORY TEST; MEDICAL DECISION MAKING; MONOTHERAPY; MUSCLE BLEEDING; OPTIMAL DRUG DOSE; PATIENT MONITORING; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REPEATED DRUG DOSE; SECONDARY PREVENTION; SINGLE DRUG DOSE; THROMBIN TIME; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; THROMBOSIS; TREATMENT PLANNING; VALIDATION STUDY;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION TESTS; COAGULANTS; FACTOR VIIA; HEMARTHROSIS; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY;

EID: 44349188657     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01735.x     Document Type: Article

References (42)

1. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 71: 71-76.
2. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 464-520.
3. Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: Prevalence and risk factors. Blood 2004; 103: 2467-73.
4. Bolton-Maggs PH. Optimal haemophilia care versus the reality. Br J Haematol 2006; 132: 671-82.
5. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia 2006; 12 (Suppl. 6): 48-52.
6. World Federation of Hemophilia. Guidelines for the Management of Hemophilia. Available at: http://www.wfh.org/2/docs/Publications/ Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf Last accessed December 2007.
7. Agence Française de SécuritéSanitaire de Produits de Santé. Développement des inhibiteurs et prise en charge chez les patients hémophiles traités par Facteur VIII ou IX d'origine plasmatique ou recombinante. May 2006. Available at: http://agmed.sante.gouv.fr/pdf/5/dev-inhibiteur-hemophile-facteur8.pdf.
8. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
9. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
10. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
11. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1: 450-5.
12. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
13. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
14. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
15. Lee D, Yoon BS, Spotts G, Ewenstein BM. Assessment of thrombotic adverse events (TAES) with activated prothrombin complex concentrates (APCCS): 17 year experience. J Thromb Haemost 2007; 5 (Suppl. 2): Abstract P-T-157.
16. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: Update of our previous experience. Haemophilia 2007; 13: 244-8.
17. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002; 88: 60-65.
18. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak, and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 402-13.
19. Tomokiyo K, Nakatomi Y, Araki T et al. A novel therapeutic approach combining human plasma-derived factors VIIa and X for haemophiliacs with inhibitors: Evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor VIIa alone. Vox Sang 2003; 85: 290-9.
20. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors'Organisation. Br J Haematol 2006; 133: 591-605.
21. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
22. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
23. Lisman T, Mosnier LO, Lambert T et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99: 175-9.
24. Barrowcliffe TW, Cattaneo M, Podda GM et al. New approaches for measuring coagulation. Haemophilia 2006; 12 (Suppl. 3): 76-81.
25. Shima M. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis. Semin Hematol 2004; 1 (Suppl. 1): 125-31.
26. Matsumoto T, Shima M, Takeyama M et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost 2006; 4: 377-84.
27. Shima M, Matsumoto T, Fukuda K et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Haemost 2002; 87: 436-41.
28. Kasuda S, Tanaka I, Shima M et al. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors. Haemophilia 2004; 10: 341-6.
29. Ovanesov MV, Krasotkina JV, Ul'yanova LI et al. Hemophilia A and B are associated with abnormal spatial dynamics of clot growth. Biochim Biophys Acta 2002; 1572: 45-57.
30. Ovanesov MV, Lopatina EG, Saenko EL et al. Effect of factor VIII on tissue factor-initiated spatial clot growth. Thromb Haemost 2003; 89: 235-42.
31. Bordet J, Plantier J, Ovanesov M, Volpert V, Ataullakhanov F, Negrier C. Wall clot growth in plasma: Effect of high doses recombinant FVIIa. J Thromb Haemost 2007; 5 (Suppl. 2): Abstract P-M-170.
32. Sørensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
33. Sørensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; 11 (Suppl. 1): 1-6.
34. Ingerslev J, Poulsen LH, Sørensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003; 9: 348-52.
35. Hayashi T, Tanaka I, Shima M et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10: 397-400.
36. Hemker HC, Giesen P, Al Dieri R et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
37. McIntosh JH, Owens D, Lee CA, Raut S, Barrowcliffe TW. A modified thrombin generation test for the measurement of factor VIII concentrates. J Thromb Haemost 2003; 1: 1005-11.
38. Dargaud Y, Béguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-80.
39. Al Dieri R, Peyvandi F, Santagostino E et al. The thrombogram in rare inherited coagulation disorders: Its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-82.
40. Váradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
41. Dargaud Y, Lienhart A, Negrier C Monitoring of recombinant FVIIa by thrombin generation test. J Thromb Haemost 2007; 5 (Suppl. 2): Abstract P-M-176.
42. Dargaud Y, Lienhart A, Meunier S et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: Use of the thrombin generation test in the therapeutic decision. Haemophilia 2005; 11: 552-8.